Lilly launches oral GLP‑1 pill

For years, the biggest weight-loss drugs came in pens and needles. On April 1, Eli Lilly got United States approval for Foundayo, a once-daily pill called orforglipron, and shipments through LillyDirect started on April 6. (prnewswire.com) These drugs copy a gut hormone called glucagon-like peptide-1, which tells the brain and stomach that a meal has happened. That signal usually makes people feel fuller sooner and eat less over time. (nejm.org) The hard part has been getting that hormone effect into a pill. Most glucagon-like peptide-1 drugs are fragile molecules that break down in the stomach, which is why Novo Nordisk’s oral semaglutide has to be taken on an empty stomach with a small amount of water. (nejm.org) Orforglipron takes a different route because it is a small molecule rather than a peptide, which means it is built more like a conventional tablet drug. Lilly says Foundayo can be taken any time of day without food or water restrictions. (prnewswire.com) (lilly.com) In Lilly’s phase 3 ATTAIN-1 trial, adults on the highest 36 milligram dose lost 11.2% of body weight at 72 weeks, compared with 2.1% on placebo. Lilly translated that into an average loss of 27 pounds for people on the top dose. (nejm.org) (prnewswire.com) The side effects looked familiar because they matched the stomach problems seen with injectable drugs in the same family. In the phase 3 study, nausea, diarrhea, constipation, vomiting, and indigestion were the most common adverse events, and the label carries a boxed warning about thyroid C-cell tumors. (nejm.org) (lilly.com) The approval is broad enough to cover two large groups: adults with obesity, and adults who are overweight if they also have at least one weight-related medical problem. The label says the pill is meant to be used with a reduced-calorie diet and increased physical activity. (lilly.com 1) (lilly.com 2) Lilly is also using price to widen the funnel. The company said Foundayo would start at $25 a month for commercially insured patients and $149 for self-pay through LillyDirect at launch. (prnewswire.com) This is Lilly’s second approved obesity drug after Zepbound, which is an injection based on tirzepatide. Foundayo gives doctors a simpler first step for patients who want to avoid needles, and Lilly gets a second lane into the same market. (medical.lilly.com) (prnewswire.com) Lilly is already pushing the same molecule beyond weight loss. In February 2026, the company said orforglipron beat oral semaglutide on both blood sugar reduction and weight loss in a head-to-head type 2 diabetes trial published in The Lancet. (prnewswire.com) That means the real shift is not just one new brand name on the pharmacy shelf. It is that the hottest corner of obesity medicine is starting to move from refrigerated pens toward ordinary pill bottles. (prnewswire.com) (nejm.org)